Silence Therapeutics (SLN) Price & Analysis

Compare

319 Followers

SLN Stock Chart & Stats

$6.32

-$0.25(-3.72%)

At close: Jan 08 4:00 PM EST

$6.32

-$0.25(-3.72%)

Day’s Range― - ―

52-Week Range$1.97 - $8.08

Previous CloseN/A

Volume50.54K

Average Volume (3M)101.05K

Market Cap

$307.49M

Enterprise Value$159.79M

Total Cash (Recent Filing)$102.19M

Total Debt (Recent Filing)$182.00K

Price to Earnings (P/E)―

Beta1.32

Next Earnings

Mar 18, 2026

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.15

Shares Outstanding47,233,948

10 Day Avg. Volume169,902

30 Day Avg. Volume101,050

Financial Highlights & Ratios

PEG Ratio0.47

Price to Book (P/B)2.42

Price to Sales (P/S)7.51

P/FCF Ratio-4.79

Enterprise Value/Market Cap0.52

Enterprise Value/Revenue6.43

Enterprise Value/Gross Profit6.93

Enterprise Value/Ebitda-2.48

Forecast

1Y Price Target

$75.00

Price Target Upside1086.71% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Pipeline ProgressSilence's RNA interference (RNAi) pipeline momentum is accelerating driven by disciplined execution across its clinical and platform programs.

Regulatory DevelopmentsSilence Therapeutics stands to benefit from the FDA’s draft guidances, which underscore the agency’s broader acceptance of flexible trial designs and real-world evidence as key components of modern regulatory science.

Strategic PartnershipsNear-term catalysts include the potential announcement of a zerlasiran partnership, updates from ongoing AstraZeneca collaboration activities, and continued preclinical readouts from the company’s extra-hepatic platform—all of which support meaningful upside toward the target.

Bears Say

Clinical Development RisksRisks include clinical development risk tied to zerlasiran and divesiran, among other development candidates.

Commercialization ChallengesRisks include commercialization risk, reimbursement risk, pricing risk, and business development risk.

Competitive And Novel Modality RisksRisks include competitor risk and novel modality risk.

Silence Therapeutics News

Silence Therapeutics Reports Q3 2025 Financial Results

Silence Therapeutics Plc ( ($SLN) ) has released its Q3 earnings. Here is a breakdown of the information...

1M ago

SLN

Buy Rating Reaffirmed for Silence Therapeutics Amid Strong RNAi Pipeline and Financial Position

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics, with...

1M ago

SLN

Silence Therapeutics reports Q3 EPS (15c), consensus (21c)

Reports Q3 revenue $159,000, consensus $3.28M. “Silence continues to focus on operational execution, highlighted by the rapid achievement...

1M ago

SLN

Silence Therapeutics Completes Enrollment for Phase 2 Study

Silence Therapeutics ( ($SLN) ) has provided an announcement. On October 23, 2025, Silence Therapeutics announced the completion...

2M ago

SLN

Silence Therapeutics completes patient enrollment in SANRECO

Silence Therapeutics (SLN) announced it has completed patient enrollment in the SANRECO Phase 2 study of divesiran, a...

2M ago

SLN

Silence Therapeutics: Promising mRNAi GOLD Platform and Strategic Initiatives Drive Buy Rating

William Blair analyst Myles Minter has maintained their bullish stance on SLN stock, giving a Buy rating on...

2M ago

SLN

Silence Therapeutics: Strong Growth Potential with Promising Clinical Advances and Strategic Collaborations

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Silence Therapeutics. The associated price target...

3M ago

SLN

Michael Davidson Resigns from Silence Therapeutics Board

The latest announcement is out from Silence Therapeutics ( ($SLN) ). On August 11, 2025, Michael Davidson resigned...

4M ago

SLN

Buy Rating for Silence Therapeutics: Promising siRNA Therapies and Strategic Pipeline Prioritization

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Silence Therapeutics, retaining the price target of...

4M ago

SLN

Private Markets: Canva draws attention as IPO candidate following Figma debut

Canva is gaining significant attention as a potential IPO candidate. The rising investor enthusiasm around the design-software giant...

4M ago

CAI

Silence Therapeutics Reports Q2 2025 Progress and Financials

Silence Therapeutics Plc ( ($SLN) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

SLN

Silence Therapeutics reports Q2 EPS (19c), consensus (21c)

Reports Q2 revenue $224,000, consensus $3.38M. “The updated data we presented at EHA this past quarter were highly...

4M ago

SLN

Silence Therapeutics Passes Key Resolutions at AGM

Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On June 26, 2025, Silence Therapeutics held its Annual...

6M ago

SLN

Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs

Silence Therapeutics (SLN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

6M ago

SLN

SLN FAQ

What was Silence Therapeutics’s price range in the past 12 months?

Silence Therapeutics lowest stock price was $1.97 and its highest was $8.08 in the past 12 months.

What is Silence Therapeutics’s market cap?

Silence Therapeutics’s market cap is $307.49M.

When is Silence Therapeutics’s upcoming earnings report date?

Silence Therapeutics’s upcoming earnings report date is Mar 18, 2026 which is in 94 days.

How were Silence Therapeutics’s earnings last quarter?

Silence Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.187 by $0.037.

Is Silence Therapeutics overvalued?

According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Silence Therapeutics pay dividends?

Silence Therapeutics does not currently pay dividends.

What is Silence Therapeutics’s EPS estimate?

Silence Therapeutics’s EPS estimate is -0.2.

How many shares outstanding does Silence Therapeutics have?

Silence Therapeutics has 47,233,948 shares outstanding.

What happened to Silence Therapeutics’s price movement after its last earnings report?

Silence Therapeutics reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.187. Following the earnings report the stock price went up 3.365%.

Which hedge fund is a major shareholder of Silence Therapeutics?

Currently, no hedge funds are holding shares in SLN

Silence Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-30.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Silence Therapeutics

Silence Therapeutics (SLN) is a biotechnology company focused on developing innovative RNA interference (RNAi) therapeutics to treat a range of diseases, including liver diseases and rare disorders. The company harnesses its proprietary mRNA-targeted platform to create targeted therapies that can modulate gene expression, offering potential treatments for conditions with significant unmet medical needs. Silence Therapeutics operates primarily in the pharmaceutical sector, working on drug development and partnerships with other biotechnology firms.

Silence Therapeutics (SLN) Earnings & Revenues

Historic Earnings Reports

SLN Stock 12 Month Forecast

Average Price Target

$75.00

▲(1086.71% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","76":"$76","19.75":"$19.75","38.5":"$38.5","57.25":"$57.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,19.75,38.5,57.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.59,11.852307692307692,17.114615384615384,22.376923076923077,27.639230769230767,32.901538461538465,38.16384615384615,43.42615384615384,48.68846153846154,53.950769230769225,59.213076923076926,64.47538461538461,69.7376923076923,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.59,11.852307692307692,17.114615384615384,22.376923076923077,27.639230769230767,32.901538461538465,38.16384615384615,43.42615384615384,48.68846153846154,53.950769230769225,59.213076923076926,64.47538461538461,69.7376923076923,{"y":75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.59,11.852307692307692,17.114615384615384,22.376923076923077,27.639230769230767,32.901538461538465,38.16384615384615,43.42615384615384,48.68846153846154,53.950769230769225,59.213076923076926,64.47538461538461,69.7376923076923,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.92,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.77,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.59,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >